Safety of Liquid Intravenous Immunoglobulin for Neuroimmunologic Disorders in the Home Setting: A Retrospective Analysis of 1085 Infusions
| Autor: | Rup Tandan, Robert J Sterling, Michael Rigas |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Young Adult Autoimmune Diseases of the Nervous System hemic and lymphatic diseases Internal medicine Outcome Assessment Health Care medicine Retrospective analysis Humans In patient IVIG Therapy Adverse effect Aged Monitoring Physiologic Retrospective Studies Aged 80 and over Therapeutic regimen Dose-Response Relationship Drug biology business.industry Headache Immunoglobulins Intravenous General Medicine Exanthema Middle Aged Home Care Services Home setting Surgery Treatment Outcome Neurology Tolerability biology.protein Female Neurology (clinical) Antibody business |
| Zdroj: | Journal of Clinical Neuromuscular Disease. 10:52-55 |
| ISSN: | 1522-0443 |
| DOI: | 10.1097/cnd.0b013e31818b2aef |
| Popis: | Objective: To examine the overall safety of intravenous immunoglobulin (IVIG) administered according to a clinically defined, home-based therapeutic regimen in patients with neuroimmunologic diseases. Methods: A total of 1085 infusions of a new liquid IVIG 10% preparation were administered to 70 patients diagnosed with neuroimmunologic diseases over a 9-month period. These infusions were retrospectively reviewed for safety and tolerability. Results: A very favorable adverse effect (AE) rate (4.7%) was calculated over a wide range of doses (0.9–2.14 g/ kg). There were no serious AEs reported, even among patients naive to IVIG therapy. Of 51 nonserious AEs, 53% occurred in 5 patients. Conclusions: The results of this review of 1085 high-dose liquid IVIGinfusionsusingacloselymonitored,yethighly flexible, home-based therapeutic regimen indicate a very favorable tolerability profile in patients with neuroimmunologic disorders, even in those who were new to IVIG therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|